Patents by Inventor Michael Wilstermann

Michael Wilstermann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 5, 6-diaryl-pyrazine-2-amide derivatives as CBantagonists
    Patent number: 7342019
    Abstract: The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, prodrugs, solvates and crystalline forms thereof, in which R1 and R2 independently represent: a C1-6alkyl group; an optionally substituted (amino)C1-4alkyl-group; an optionally substituted non-aromatic C3-15carbocyclic group; a (C3-12cycloalkyl)C1-3alkyl-group; a group —(CH2)r(phenyl)s in which r is 0, 1, 2, 3 or 4, s is 1 when r is 0 otherwise s is 1 or 2 and the phenyl groups are optionally independently substituted by Z; naphthyl; anthracenyl; an optionally substituted saturated 5 to 8 membered heterocyclic group containing one nitrogen and optionally one of the following: oxygen, sulphur or an additional nitrogen; 1-adamantylmethyl; a group —(CH2)t Het in which t is 0, 1, 2, 3 or 4, and the alkylene chain is optionally substituted and Het represents an optionally substituted aromatic heterocycle; or R1 represents H and R2 is as defined above; or R1 and R2 together with the nitrogen atom to which they are atta
    Type: Grant
    Filed: December 18, 2002
    Date of Patent: March 11, 2008
    Assignee: AstraZeneca AB
    Inventors: Anna Ingrid Kristina Berggren, Stig Jonas Boström, Stig Thomas Elebring, Peter Greasley, Emma Terricabras, Johan Michael Wilstermann
  • 2,3-Substituted 5,6-diaryl-pyrazine derivatives as cb1 modulators
    Publication number: 20070093505
    Abstract: The present invention relates to 2,3-substituted-4,5-diarylpyrazine compounds and their compositions, processes for their preparation, and their use in the treatment of obesity and psychiatric and neurological disorders.
    Type: Application
    Filed: June 16, 2004
    Publication date: April 26, 2007
    Applicant: ASTRAZENECA AB
    Inventors: Leifeng Cheng, Michael Wilstermann
  • 3,7-diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias
    Patent number: 7144914
    Abstract: There is provided compounds of formula (I) wherein R1 to R4, Ra to Rf, A and B have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
    Type: Grant
    Filed: January 29, 2002
    Date of Patent: December 5, 2006
    Assignee: Astrazeneca AB
    Inventors: Magnus Björsne, Fritiof Pontén, Gert Strandlund, Peder Svensson, Michael Wilstermann
  • 3,8-Diazabicyclo[3.2.1]octanes and their use in the treatment of cardiac arrhythmias
    Patent number: 7012074
    Abstract: There is provided compounds of formula (I), wherein R1, R2 and Ra to Rb have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
    Type: Grant
    Filed: October 18, 2001
    Date of Patent: March 14, 2006
    Assignee: AstraZeneca AB
    Inventors: Magnus Bjorsne, Kurt-Jürgen Hoffmann, Fritiof Pontén, Gert Strandlund, Peder Svensson, Michael Wilstermann
  • 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias
    Publication number: 20040053986
    Abstract: There is provided compounds of formula (I wherein R1 to R4, Ra to Rf, A and B have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
    Type: Application
    Filed: July 31, 2003
    Publication date: March 18, 2004
    Inventors: Magnus Bjorsne, Fritiof Ponten, Gert Strandlund, Peder Svensson, Michael Wilstermann
  • 3,8-Diazabicyclo[3.2.1]octanes and their use in the treatment of cardiac arrhythmias
    Publication number: 20040023971
    Abstract: There is provided compounds of formula (I), wherein R1, R2 and Ra to Rb have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
    Type: Application
    Filed: May 8, 2003
    Publication date: February 5, 2004
    Inventors: Magnus Bjorsne, Kurt-Jurgen Hoffmann, Fritiof Ponten, Gert Strandlund, Peder Svensson, Michael Wilstermann